Advice

in the absence of a submission from the holder of the marketing authorisation.

temsirolimus (Torisel®) is not recommended for use within NHS Scotland.

Licensed indication under review: the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma [MCL].

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Download detailed advice45KB (PDF)

Download

Medicine details

Medicine name:
temsirolimus (Torisel)
SMC ID:
617/10
Indication:
Relapsed and/or refractory mantle cell lymphoma
Pharmaceutical company
Wyeth Pharmaceuticals
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
12 April 2010